The high expression of PKM2 has been shown to enhance drug response to epirubicin and 5-fluorouracil in BC [155], whereas a decrease in PKM2 levels/activity contributes to cisplatin/oxaliplatin resistance in cervical cancer, colorectal cancer, and gastric cancer cells [153,156,157]. Here, PKM is linked to cervical carcinoma.